0.26 (-%)
As of Dec 13, 2024
Source:
We are a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs. We are developing a novel and proprietary class of product candidates, led by KORSUVA (CR845/difelikefalin), a first-in-class KOR agonist that targets KORs located in the peripheral nervous system and on immune cells.
Country | United States |
Headquarters | stamford, connecticut |
Phone Number | 203-406-3700 |
Industry | manufacturing |
CEO | Christopher Posner |
Website | www.caratherapeutics.com |